SCHEDULE: RTW Investments Discloses 4.9% Stake in Apogee Therapeutics

RTW Investments, LP and Roderick Wong, M.D. have reported a 4.9% beneficial ownership stake in Apogee Therapeutics, Inc. common stock.

Summary

• RTW Investments, LP and Roderick Wong, M.D. collectively reported beneficial ownership of 2,712,097 shares of Apogee Therapeutics, Inc. common stock.
• This represents 4.9% of the company's outstanding common stock.
• The ownership percentage is calculated based on 54,833,587 shares outstanding as of November 3, 2025, as reported in Apogee Therapeutics' Form 10-Q filed on November 10, 2025.
• The reporting persons share both voting and dispositive power over all 2,712,097 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant stake by a reputable investment firm like RTW Investments suggests a belief in Apogee Therapeutics' underlying value and future prospects, without indicating any immediate activist intentions.

Positives

• A significant institutional investor, RTW Investments, LP, has taken a substantial stake (4.9%) in Apogee Therapeutics, indicating potential confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic, rather than activist, position.

Future Outlook

NA

Management Comments

• To the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

StockSavvy.ai notes that a 4.9% stake by a specialized healthcare investment firm like RTW Investments in a biotechnology company such as Apogee Therapeutics often signals a vote of confidence in the company's pipeline, management, or market potential. This level of ownership, just below the 5% threshold that would trigger a more detailed Schedule 13D filing (implying activist intent), suggests a passive investment strategy focused on long-term value appreciation within the biotech sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially attract further institutional interest, positively impacting shareholder sentiment.
• Management: The presence of a substantial, yet passive, institutional investor like RTW Investments may provide a level of oversight and strategic support without immediate pressure for operational changes.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by RTW Investments is a positive indicator of confidence in Apogee Therapeutics, this filing alone does not provide sufficient operational or financial data to warrant a 'buy' or 'strong buy' recommendation. It primarily signals a long-term, passive investment. Investors should 'hold' and await further operational updates and financial results from Apogee Therapeutics to assess the company's fundamental performance and future trajectory.

Keywords

Apogee Therapeutics, RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment, Institutional Investor